

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

David C. BAULCOMBE et al.

Application No.: 10/805,804

Filed: March 22, 2004

For: GENE SILENCING

Confirmation No.: 9959

Art Unit: 1638

Examiner: Ashwin D. Mehta, Ph.D.

AMENDMENT UNDER 37 C.F.R. § 1.111

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to an Office action herein, mailed 26 June 2007, time for response to which was set to expire 26 September 2007. A petition for an extension of time of two (2) months until 26 November 2007 is attached hereto, along with the required fee. The pending claims, claims 116-124, were rejected. Careful consideration has been given to the grounds for rejection, and the following amendment and discussion are submitted in response. Reconsideration is respectfully requested.

Enclosures:

1. Copy of Baulcombe declaration
2. Martinez, J., *et al.*, *Cell* (2002) 110:563-574
3. Chapter 13 from RNAi – A Guide to Gene Silencing, G. J. Hanson, *et al.*, CSHL Press (2003) (authored by Thomas Tuschl)
4. Paddison, P. J. *et al.*, *Genes & Dev.* (2002) 16:948-958
5. Tuschl, T., *et al.*, *Genes & Dev* (1999) 13:3191-3197
6. Zamore, P. D., *et al.*, *Cell* (2000) 101:25-33
7. *Amgen, Inc. v. Hoechst, Marion Roussel*, 314 F3d 1313, 65 USPQ2d 1385 (Fed. Cir. 2003)
8. *In re Jones*, 958 F2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992)
9. New Oath specific to this case.